Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/bioinformatics/btaa224 http://scihub22266oqcxt.onion/10.1093/bioinformatics/btaa224 32239142!7184403!32239142     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32239142&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32239142.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Bioinformatics 2020 ; 36 (11): 3295-3298 Nephropedia Template TP {{tp|p=32239142|t=2020. Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus |pdf=|usr=}}{{32239142}} gab.com Text Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus JO: Bioinformatics http://www.kidney.de/pget.php?&tw=1&pmid=32239142 #FOAvip MOTIVATION: Since December 2019, the newly identified coronavirus SARS-CoV-2 has caused a massive health crisis worldwide and resulted in over 70 000 COVID-19 infections so far. Clinical drugs targeting SARS-CoV-2 are urgently needed to decrease the high fatality rate of confirmed COVID-19 patients. Traditional de novo drug discovery needs more than 10 years, so drug repurposing seems the best option currently to find potential drugs for treating COVID-19. RESULTS: Compared with traditional non-covalent drugs, covalent drugs have attracted escalating attention recent years due to their advantages in potential specificity upon careful design, efficiency and patient burden. We recently developed a computational protocol named as SCAR (steric-clashes alleviating receptors) for discovering covalent drugs. In this work, we used the SCAR protocol to identify possible covalent drugs (approved or clinically tested) targeting the main protease (3CLpro) of SARS-CoV-2. We identified 11 potential hits, among which at least six hits were exclusively enriched by the SCAR protocol. Since the preclinical or clinical information of these identified drugs is already available, they might be ready for being clinically tested in the treatment of COVID-19. CONTACT: senliu.ctgu@gmail.com. Twit Text FOAVip Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus ????Bioinformatics http://www.kidney.de/pget.php?&tw=1&pmid=32239142 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32239142 #FOAvip English Wikipedia <ref>{{Cite pmid|32239142}}</ref> Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus #MMPMID32239142 Liu S; Zheng Q; Wang Z Bioinformatics 2020[Jun]; 36 (11): 3295-3298 PMID32239142show ga MOTIVATION: Since December 2019, the newly identified coronavirus SARS-CoV-2 has caused a massive health crisis worldwide and resulted in over 70 000 COVID-19 infections so far. Clinical drugs targeting SARS-CoV-2 are urgently needed to decrease the high fatality rate of confirmed COVID-19 patients. Traditional de novo drug discovery needs more than 10 years, so drug repurposing seems the best option currently to find potential drugs for treating COVID-19. RESULTS: Compared with traditional non-covalent drugs, covalent drugs have attracted escalating attention recent years due to their advantages in potential specificity upon careful design, efficiency and patient burden. We recently developed a computational protocol named as SCAR (steric-clashes alleviating receptors) for discovering covalent drugs. In this work, we used the SCAR protocol to identify possible covalent drugs (approved or clinically tested) targeting the main protease (3CLpro) of SARS-CoV-2. We identified 11 potential hits, among which at least six hits were exclusively enriched by the SCAR protocol. Since the preclinical or clinical information of these identified drugs is already available, they might be ready for being clinically tested in the treatment of COVID-19. CONTACT: senliu.ctgu@gmail.com. |*Betacoronavirus/drug effects[MESH] |*Coronavirus[MESH] |*Coronavirus Infections/drug therapy/enzymology[MESH] |*Cysteine Endopeptidases/drug effects[MESH] |*Drug Delivery Systems[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/drug therapy/enzymology[MESH] |*Severe acute respiratory syndrome-related coronavirus[MESH] |*Viral Nonstructural Proteins/drug effects[MESH] |COVID-19[MESH] |Coronavirus 3C Proteases[MESH] |Humans[MESH] |Peptide Hydrolases/drug effects[MESH]Potential covalent drugs targeting the main protease of the SARS-CoV-2(epmc).pdf DeepDyve Pubget Overpricing